Hanna Tukachinsky

Translational scientist at Foundation Medicine | Boston by Foot tour guide as a side hobby | Opinions my own

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

I am glad these results are out.

Guidelines jumped the gun on incorporating sidedness for mCRC treatment.

Insurance companies started denying therapy even when molecular data pointed otherwise..

Patients suffered.

#gi24

[Pashtoon Kasi MD, MS @pashtoonkasi]

Just published @CCR_AACR

Is it a myth🐉that you can’t detect fusions on #ctDNA?

👇🏾Presenting one of the largest datasets on #LiquidBiopsies & Fusion🖇️detection

53,842 patients
1️⃣4️⃣% had a pathogenic rearrangement detected
Shedding💦matters

@OncoAlert

https://t.co/1yw4j8UnFr

[Hanna Tukachinsky @HTukachinsky]

Such an amazing story! The true power of precision medicine and liquid biopsy showcased: https://t.co/b5sGmqv5gH

[Pashtoon Kasi MD, MS @pashtoonkasi]

@VivekSubbiah @geoff_oxnard @HTukachinsky @curecc @DrawImpacts By popular demand, here’s an update:
👇🏾Response to #RET🖇️⛔️💊 after just 2 weeks. From a CA19-9 of nearly 5000 down to ~1000.

Not surprising when the driver is a fusion, the responses are brisk, robust, and durable. @curecc

Remember this is 3rd line #cholangiocarcinoma. 🙌🏾

[Geoff Oxnard MD @geoff_oxnard]

🎉 My first paper in JLB @isliquidbiopsy! 🤓

A pleasure to collaborate with SCRUM-Japan to describe pan-tumor bTMB 🩸concordance w TMB 🔬& identification of cancer pts w better outcomes on IO:
https://t.co/rv7sUBAsma

[Hanna Tukachinsky @HTukachinsky]

Thank you @arafflemd et al. for collaborating on this important work about BRAF beyond V600E (mutations and fusions): an exciting, potentially targetable biomarker that has been largely overlooked in #prostatecancer.

[Alex Chehrazi-Raffle, MD @arafflemd]

6.We hope our findings will fuel future exploration of targeting BRAF alts in PCa! Many thanks to @HTukachinsky & #justinhwanglab for their invaluable contributions, and a huge shout out to @EAntonarakis, @neerajaiims , & @montypal for their unwavering support and mentorship 🙏🏼

[Foundation Medicine @FoundationATCG]

The level of circulating tumor DNA (ctDNA) shed by a patient’s specific tumor informs the accuracy of blood-based CGP test results. Through a tumor fraction algorithm, our scientists developed a method for quantifying ctDNA in each blood sample: https://t.co/OX9hmoup55 #ASCO23

[Pashtoon Kasi MD, MS @pashtoonkasi]

Appreciate the kind words!

A good poster is a health hazard. We talked about liquid biopsies for over 4 hours! Had to be booted🥾out of the poster hall.

And the slow walk & ongoing questions shows the VERY HIGH enthusiasm and education needed about #ctDNA. #ASCO23 @OncoAlert

[Pashtoon Kasi MD, MS @pashtoonkasi]

@geoff_oxnard @VivekSubbiah @Relay_Tx @BrentonMar I recently heard that ALL the 3 phase-3 trials continue to have very slow accrual🚶‍♀️. 2 have shut down due to slow accrual!

Took these companies a long time to realize that you could enroll ctDNA➕.

1/3rd of cholangio; not enough tissue for NGS. 💡🩸 can fill the void.#ASCO23

[Geoff Oxnard MD @geoff_oxnard]

Bravo @JoelNealMD , love this paradigm @CharuAggarwalMD has championed: early LBx 🩸🧬 based on a *clinical diagnosis* of lung cancer, in parallel to pathologic diagnosis🔬!

[Hanna Tukachinsky @HTukachinsky]

Thought-provoking commentary "Alpelisib Efficacy without Cherry-PI3King Mutations" on our paper with @hoperugo and @geoff_oxnard in current CCR issue #breastcancer @FoundationATCG

[Miller Lab at Dartmouth @TMillerLab]

Congratulations to Steven for his commentary in CCR!
https://t.co/XuAryyaRBS

[Todd 〽️ Morgan, MD @wandering_gu]

Beautiful summary of mCRPC treatment options with recommended algorithms by @Silke_Gillessen #GU23

[Hanna Tukachinsky @HTukachinsky]

@arafflemd @FoundationATCG @EAntonarakis @neerajaiims @montypal Congrats @arafflemd! Really important work to highlight a potentially targetable genomic alteration in what appears to be a unique subset of patients. Thank you for your collaboration!

[Geoff Oxnard MD @geoff_oxnard]

Unique spectrum of BRAF alts in prostate cancer!

👉3% BRAF activated, mostly rearrangements and K601E.
👉Diverse BRAF fusions detected both in tissue DNA (F1CDx) and liquid ctDNA (F1LCDx).

Love the teamwork here!🙌 @neerajaiims @montypal @EAntonarakis @HTukachinsky

[Hanna Tukachinsky @HTukachinsky]

Some next-gen BRAF inhibitors out there already in phase 1/2 trials 🤞Hoping for a future with targeted therapies beyond PARP inhibitors for PC!

[Emmanuel Antonarakis @EAntonarakis]

@geoff_oxnard @neerajaiims @montypal @HTukachinsky Now let’s develop some effective drugs to target non-V600 BRAF-activated cancers!!

[Hanna Tukachinsky @HTukachinsky]

Key takeaway 2:
In an analysis of real world data, these patients with non-companion diagnostic PIK3CA mutations derived benefit from addition of alpelisib to fulvestrant (similar to the companion diagnostic mutations).

[Hanna Tukachinsky @HTukachinsky]

It was an honor to collaborate with @hoperugo on a study about the extended spectrum of PIK3CA mutations in #breastcancer, and the outcomes of patients with such mutations on alpelisib (Piqray) + fulvestrant. Paper published online first in @CCR_AACR: https://t.co/G7ZDxMhVsz

[Hanna Tukachinsky @HTukachinsky]

Key takeaway 1:
1/5 of patients with PIK3CA-mutant breast cancer do not have a PIK3CA mutation on the companion diagnostic list for alpelisib (would not be detected by PCR hotspot testing)

[JCO Precision Oncology @JCOPO_ASCO]

👀 Check out what’s popular this week in #JCOPO:

Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples 👉 https://t.co/I4YrGmmyoQ @HatimHusainMD @geoff_oxnard #ctDNA #lcsm

[Hanna Tukachinsky @HTukachinsky]

Nice study from my FMI colleagues. Improving precision medicine includes identifying futility biomarkers for SOC!

[Ethan Sokol @EthanSokol]

Our manuscript went live today. APOBEC mutational signatures in ER+/HER2- breast cancer are associated with poor prognosis on SOC CDK4/6i + ET with a subset of patients responding to immune checkpoint inhibitors. https://t.co/Ov0RC6Wnhs

[Hanna Tukachinsky @HTukachinsky]

@taliawegman @HatimHusainMD @geoff_oxnard @FoundationATCG @taliawegman Yes, these were all blood samples sent in as part of routine clinical care from US-based clinics. Do you have interest in liquid biopsies using other fluid types?